(Q33374095)

26 July 2017

title

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma (English)

1 reference

26 July 2017

1 reference

Carlos Frangié

1

1 reference

26 July 2017

Carmen Lefaucheur

2

1 reference

26 July 2017

Jacques Medioni

3

1 reference

26 July 2017

Christian Jacquot

4

1 reference

26 July 2017

Garry S Hill

5

1 reference

26 July 2017

Dominique Nochy

6

1 reference

26 July 2017

publication date

1 February 2007

1 reference

Lancet Oncology Commission

26 July 2017

published in

1 reference

26 July 2017

volume

8

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

177-178

1 reference

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

A new model of renal microvascular endothelial injury

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970037-2

7 January 2021

10.1016/S1470-2045(07)70037-2

Identifiers

DOI

1 reference

26 July 2017

1 reference